Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis
- PMID: 16960920
Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis
Abstract
Objective: To assess if joint damage at 2 years after diagnosis in patients with systemic juvenile idiopathic arthritis (SJIA) can be predicted by clinical or laboratory features assessed up to 3 or 6 months after diagnosis.
Methods: Medical records from 70 children were retrospectively reviewed. The primary outcome measure was presence of joint damage at 2 years after diagnosis (JD2) as defined by presence of erosions or fusion in one or more joints. Potential predictor variables for JD2 in the first 3 and 6 months after diagnosis consisted of the highest observed white blood cell count, platelet count, erythrocyte sedimentation rate, active joint count, and presence of symptomatic pulmonary or cardiac disease or macrophage activation syndrome, and treatment data.
Results: The outcome of interest, JD2, was identified in 15/70 patients. Classification-tree analysis identified a pair of variables (highest observed platelet count and number of active joints) measured within the first 3 months after diagnosis that together predicted progression to JD2 with an estimated sensitivity of 87%, specificity of 82%, and positive predictive value of 57%. Multivariate logistic regression analyses at 3 months found that higher quantities of joints with active arthritis and early use of methotrexate (MTX) were factors significantly associated with increased odds of progression to JD2 (active joints odds ratio = 1.08, 95% CI 1.00-1.16, p = 0.04; MTX OR = 11.85, 95% CI 1.89-74.26, p = 0.01). Unsupervised cluster analysis identified 2 major phenotypes of patients at 3 months characterized by different ages at onset, acute phase markers, active joint counts, and presence of serositis. These phenotypes differed 3-fold in proportion of subjects progressing to JD2 (p < 0.05).
Conclusion: By 3 months after diagnosis, a clinical phenotype based on active joint count and platelet count may be prognostic of an increased risk of progression to JD2. Use of corticosteroids did not appear to change the risk of joint damage. In contrast, the presence of serositis appeared to be associated with decreased risk of joint damage.
Similar articles
-
Prognostic factors in juvenile rheumatoid arthritis: a case-control study revealing early predictors and outcome after 14.9 years.J Rheumatol. 2003 Feb;30(2):386-93. J Rheumatol. 2003. PMID: 12563700
-
The early pattern of joint involvement predicts disease progression in children with oligoarticular (pauciarticular) juvenile rheumatoid arthritis.Arthritis Rheum. 2002 Oct;46(10):2708-15. doi: 10.1002/art.10544. Arthritis Rheum. 2002. PMID: 12384930
-
High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis.J Rheumatol. 2000 Aug;27(8):2018-24. J Rheumatol. 2000. PMID: 10955346
-
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.J Pediatr. 2005 May;146(5):598-604. doi: 10.1016/j.jpeds.2004.12.016. J Pediatr. 2005. PMID: 15870661 Review.
-
Temporomandibular joint arthritis in juvenile idiopathic arthritis: the forgotten joint.Curr Opin Rheumatol. 2006 Sep;18(5):490-5. doi: 10.1097/01.bor.0000240360.24465.4c. Curr Opin Rheumatol. 2006. PMID: 16896288 Review.
Cited by
-
Alternative activation in systemic juvenile idiopathic arthritis monocytes.Clin Immunol. 2012 Mar;142(3):362-72. doi: 10.1016/j.clim.2011.12.008. Epub 2011 Dec 28. Clin Immunol. 2012. PMID: 22281427 Free PMC article.
-
Application of the international league against rheumatism classification criteria for systemic juvenile idiopathic arthritis as a prognostic factor in patients with adults-onset Still's disease.Pediatr Rheumatol Online J. 2018 Jan 25;16(1):9. doi: 10.1186/s12969-018-0225-1. Pediatr Rheumatol Online J. 2018. PMID: 29370863 Free PMC article.
-
Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis.BMC Med. 2012 Oct 23;10:125. doi: 10.1186/1741-7015-10-125. BMC Med. 2012. PMID: 23092393 Free PMC article.
-
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis.Arthritis Rheumatol. 2014 Sep;66(9):2570-9. doi: 10.1002/art.38699. Arthritis Rheumatol. 2014. PMID: 24839206 Free PMC article. Clinical Trial.
-
Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states.Clin Immunol. 2010 Feb;134(2):206-16. doi: 10.1016/j.clim.2009.09.010. Epub 2009 Oct 29. Clin Immunol. 2010. PMID: 19879195 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical